PJP - PowerShares Dynamic Pharmaceuticals Portfolio

NYSEArca - Nasdaq Real Time Price. Currency in USD
62.5600
-0.4600 (-0.7299%)
At close: 3:53PM EDT
Stock chart is not supported by your current browser
Previous Close63.0200
Open62.8500
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range62.4928 - 63.0400
52 Week Range57.9300 - 71.4200
Volume16,512
Avg. Volume47,898
Net Assets548.78M
NAV62.36
PE Ratio (TTM)N/A
Yield0.70%
YTD Return-2.67%
Beta (3y)1.04
Expense Ratio (net)0.56%
Inception Date2005-06-23
Trade prices are not sourced from all markets
  • Projprzem SA. (WSE:PJP) Delivered A Better ROE Than The Industry, Here’s Why
    Simply Wall St.21 hours ago

    Projprzem SA. (WSE:PJP) Delivered A Better ROE Than The Industry, Here’s Why

    Projprzem SA. (WSE:PJP) delivered an ROE of 10.70% over the past 12 months, which is an impressive feat relative to its industry average of 5.43% during the same period. WhileRead More...

  • Is Projprzem SA. (WSE:PJP) A Financially Sound Company?
    Simply Wall St.8 days ago

    Is Projprzem SA. (WSE:PJP) A Financially Sound Company?

    While small-cap stocks, such as Projprzem SA. (WSE:PJP) with its market cap of ZŁ95.72M, are popular for their explosive growth, investors should also be aware of their balance sheet toRead More...

  • What Led to Increase in US Trade Deficit in February?
    Market Realist8 days ago

    What Led to Increase in US Trade Deficit in February?

    The US Bureau of Economic Analysis publishes a monthly report on US international trade in goods and services that details the changes in imports and exports. The latest report indicated that the goods and services deficit was $57.6 billion in February, an increase of $0.9 billion from $56.7 billion in January. The trade deficit is currently at a nine-year high, and this could be cited as one of the key reasons the Trump administration has taken steps to increase trade barriers.

  • A Look at Eli Lilly’s 1Q18 Stock Performance
    Market Realist10 days ago

    A Look at Eli Lilly’s 1Q18 Stock Performance

    Eli Lilly and Company (LLY) is a US pharmaceutical company with headquarters in Indianapolis, Indiana. The company specializes in products for both human health and animal health.

  • Analysts’ Recommendations for Eli Lilly in March 2018
    Market Realist18 days ago

    Analysts’ Recommendations for Eli Lilly in March 2018

    As we discussed earlier, Eli Lilly and Company (LLY) surpassed Wall Street analysts’ estimates for EPS (earnings per share) and revenue in 4Q17. Eli Lilly also surpassed analysts’ estimates for EPS and revenue for 2017, reporting EPS of $4.28 on revenue of ~$22.9 billion compared to the estimate of $4.22 on revenue of ~$22.7 billion for the year. In 1Q18, Wall Street analysts expect EPS of $1.14 on revenue of $5.5 billion for the company, a ~5.0% rise compared to 1Q17.

  • A Look at Bristol-Myers Squibb’s Eliquis in 4Q17
    Market Realist23 days ago

    A Look at Bristol-Myers Squibb’s Eliquis in 4Q17

    What’s Behind Bristol-Myers Squibb’s Valuation

  • How to Invest in Healthcare Stocks the Easy Way
    Motley Fool28 days ago

    How to Invest in Healthcare Stocks the Easy Way

    Here are several smart ways to invest in the companies that keep people healthy.

  • How Pfizer Performed across Geographies during 4Q17
    Market Realistlast month

    How Pfizer Performed across Geographies during 4Q17

    As discussed earlier, Pfizer’s (PFE) revenue rose ~1% to $13.7 billion during 4Q17 driven by increased sales of its Innovative Health products. It reflects revenues for both Pfizer’s Innovative Health and Essential Health segments in 4Q17. Pfizer reported a fall of ~4% in its US sales in 4Q17, while its sales outside US markets reported a 5% revenue rise in the quarter.

  • Johnson & Johnson’s Revenues in 4Q17
    Market Realist2 months ago

    Johnson & Johnson’s Revenues in 4Q17

    Changes in Johnson & Johnson's Valuation in February 2018

  • Behind Valeant Pharmaceuticals’ Business Segments
    Market Realist2 months ago

    Behind Valeant Pharmaceuticals’ Business Segments

    Valeant Pharmaceuticals (VRX) operates through three segments: Bausch and Lomb (or the International segment), Branded Prescriptions, and US Diversified Products. This segment consists of Valeant’s US sales of pharmaceutical products, over the counter products, and medical devices, which primarily consist of ophthalmics, surgical, consumer products, and the sales of branded, generic, over-the-counter, and medical devices in Canada, Europe, Asia, Australia, New Zealand, Latin America, Africa, and the Middle East. With the sale of Dendreon in June 2017, Valeant exited its oncology business, which was a part of the Branded Prescriptions segment.

  • Johnson & Johnson’s 4Q17 Guidance for Fiscal 2018
    Market Realist3 months ago

    Johnson & Johnson’s 4Q17 Guidance for Fiscal 2018

    Must-Read Notes on Johnson & Johnson’s 4Q17 Earnings

  • Investopedia3 months ago

    Top 5 Pharmaceutical ETFs for 2018

    Details on the five top healthcare pharmaceutical ETFs for 2018.

  • President Trump’s State of the Union Speech Is Market Positive
    Market Realist3 months ago

    President Trump’s State of the Union Speech Is Market Positive

    In his first State of the Union speech, President Trump didn’t have any surprises for the markets (SPY). At the annual State of the Union meeting, President Trump addressed a joint session of Congress. President Trump stayed away from any surprise statements that could have spooked the markets.

  • Vermont Legalizes Recreational Marijuana on January 22, 2018
    Market Realist3 months ago

    Vermont Legalizes Recreational Marijuana on January 22, 2018

    On January 22, 2018, Vermont decriminalized the possession of marijuana for adults 21 and older. With increasing attention on the legalization of recreational marijuana in recent months, Vermont became the ninth state in the US to legalize marijuana for recreational purposes. This move comes almost six years after recreational marijuana became legal in Colorado and Washington.

  • A Look into Amgen’s Collaborations in 2H17
    Market Realist3 months ago

    A Look into Amgen’s Collaborations in 2H17

    How Is Amgen Positioned for 2018?

  • Investopedia4 months ago

    Top 5 Pharmaceutical ETFs for 2018

    Details on the five top healthcare pharmaceutical ETFs for 2018.

  • Market Realist5 months ago

    Merck’s Immunology and Oncology Drugs, Post-3Q17

    In 3Q17, Remicade generated revenue of $214 million, a ~31% fall YoY (year-over-year) and 3% growth QoQ (quarter-over-quarter). During the first nine months of 2017, Remicade reported revenue of $651 million,…...

  • Market Realist5 months ago

    What Led to the Rise in the US Trade Deficit in September?

    The latest report was released on November 3 and indicated that the goods and services deficit was $43.5 billion in September, or $0.7 billion higher than in August.

  • Investopedia6 months ago

    Top 3 Pharmaceutical ETFs of 2017

    Details on the three top healthcare pharmaceutical ETFs in 2017.

  • Market Realist7 months ago

    How Merck’s Diabetes Portfolio Performed in 2Q17

    Merck’s (MRK) diabetes portfolio includes drugs used for controlling the blood sugar levels for patients with diabetes.

  • Why Jazz Pharmaceuticals’ Vyxeos Could Boost Revenue Growth in 2018
    Market Realist7 months ago

    Why Jazz Pharmaceuticals’ Vyxeos Could Boost Revenue Growth in 2018

    In August 2017, JAZZ's Vyxeos liposome injection for the treatment of adult individuals with rapidly progressing or life t-AML received FDA approval.

  • Market Realist7 months ago

    Eli Lilly & Co.’s Recent Developments after Its 2Q17 Earnings

    On July 31, 2017, Eli Lilly and Boehringer Ingelheim announced that the companies would support one of the new programs by the American College of Cardiology.

  • Market Realist8 months ago

    Performance of Eli Lilly’s Endocrine Franchise in 2Q17

    Forteo is used for the treatment of osteoporosis. Forteo's sales totaled $446.7 million during 2Q17, a 22.0% increase compared to $367.6 million in 2Q16.

  • Market Realist8 months ago

    How Pfizer’s Enbrel and Xeljanz Are Positioned after 2Q17

    In August 2017, the Arthritis Advisory Committee of the FDA recommended a positive opinion for the proposed dose of Xeljanz for the treatment of individuals with active psoriatic arthritis.

  • Market Realist8 months ago

    Ligand Pharmaceuticals Focuses on Increasing Returns for Shareholders

    Ligand Pharmaceuticals has developed a product portfolio that spans more than 700 patents offering varying degrees of protection to the assets.